Alicia Secor
Directeur/Membre du Conseil chez G1 THERAPEUTICS, INC.
Fortune : - $ au 30/06/2024
Profil
Alicia Secor is currently the President, Chief Executive Officer & Director at Atalanta Therapeutics, Inc. She is also an Independent Director at G1 Therapeutics, Inc. and a Director at Orchard Therapeutics (Europe) Ltd.
Additionally, she serves as a Director at the Foundation For Prader-Willi Research, Inc. In her former roles, Ms. Secor was the President, Chief Executive Officer & Director at Catalent JNP, Inc. from 2016 to 2018.
She also served as an Independent Non-Executive Director at GW Pharmaceuticals Ltd.
from 2017 to 2021 and as an Independent Non-Executive Director at Orchard Therapeutics Plc from 2018 to 2024.
Prior to that, she was the Vice President & GM-Metabolic Diseases at Genzyme Corp.
from 1998 to 2013.
She also held the position of Chief Commercial Officer at Zafgen, Inc. from 2014 to 2016 and Chief Operating Officer & Senior Vice President at Synageva BioPharma Corp.
in 2013.
Ms. Secor completed her undergraduate degree at the University of New Hampshire and holds an MBA from D'Amore-Mckim School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
G1 THERAPEUTICS, INC.
-.--% | 13/06/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Alicia Secor
| Sociétés | Poste | Début |
|---|---|---|
| G1 THERAPEUTICS, INC. | Directeur/Membre du Conseil | 17/06/2021 |
| Foundation For Prader-Willi Research, Inc. | Directeur/Membre du Conseil | 01/11/2016 |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | - |
Atalanta Therapeutics, Inc.
 Atalanta Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Atalanta Therapeutics, Inc. develops RNA interference based therapeutics to treat neurodegenerative diseases. The company is based in Boston, MA. The company was founded by Neil Aronin, Craig C. Mello, Anastasia Khvorova, Jim Glasheen. The CEO is Alicia Secor. | Directeur Général | - |
Anciens postes connus de Alicia Secor
| Sociétés | Poste | Fin |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Directeur/Membre du Conseil | 24/01/2024 |
| GW PHARMACEUTICALS PLC | Directeur/Membre du Conseil | 05/05/2021 |
| JUNIPER PHARMACEUTICALS INC | Directeur Général | 14/08/2018 |
| LARIMAR THERAPEUTICS, INC. | Corporate Officer/Principal | 31/07/2016 |
| SYNAGEVA BIOPHARMA CORP | Directeur des opérations | 23/10/2013 |
Formation de Alicia Secor
| University of New Hampshire | Undergraduate Degree |
| D'Amore-Mckim School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| G1 THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Catalent JNP, Inc.
 Catalent JNP, Inc. Pharmaceuticals: MajorHealth Technology Catalent JNP, Inc. engages in the research and development of drugs and therapeutics. It offers analytical characterization and pre-formulation testing; formulation development; and clinical manufacturing of capsules and tablets. The company was founded in December 1986 and is headquartered in Somerset, NJ. | Health Technology |
GW Pharmaceuticals Ltd.
 GW Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology GW Pharmaceuticals Ltd. operates as an intermediate holding company and management company for investments in its subsidiaries. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| Foundation For Prader-Willi Research, Inc. | |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Atalanta Therapeutics, Inc.
Atalanta Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Atalanta Therapeutics, Inc. develops RNA interference based therapeutics to treat neurodegenerative diseases. The company is based in Boston, MA. The company was founded by Neil Aronin, Craig C. Mello, Anastasia Khvorova, Jim Glasheen. The CEO is Alicia Secor. | Commercial Services |
